Inc. (NYSE: AEON) (the “Company”), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex under a 351(k) biosimilar pathway, today announced the closing of its ...
DETROIT, Jan. 07, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: AMST), a pioneering technology company specializing in the development and marketing of B2C and B2B AI-driven solutions, today announced the ...
KBRA assigns preliminary ratings to six classes of mortgage pass-through notes from Verus Securitization Trust 2025-1 (VERUS 2025-1), a $553.2 million non-prime RMBS transaction. The underlying ...